Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest severe emphysema Stories

2013-02-25 08:27:38

MOUNTAIN VIEW, Calif., Feb. 25, 2013 /PRNewswire/ -- PneumRx, Inc., a leader in interventional pulmonology, announced the first U.S. patients treated with PneumRx's Lung Volume Reduction Coils (LVRCs) for severe emphysema. Dr. Charlie Strange, of the Medical University of South Carolina, and Dr. Frank Sciurba, of the University of Pittsburgh and UPMC, treated the first US patients in the FDA-approved RENEW Study. The RePneu® LVRC, a minimally invasive medical implant designed to treat...

2012-12-17 08:24:29

MOUNTAIN VIEW, Calif., Dec. 17, 2012 /PRNewswire/ -- PneumRx, Inc., a leader in interventional pulmonology, announced today that University Medical Center Groningen has enrolled and treated the first patients in the FDA-approved RENEW pivotal trial to evaluate the RePneu Lung Volume Reduction Coil (LVRC). The RePneu LVRC, a minimally invasive medical implant designed to treat the symptoms of severe emphysema, is intended to improve lung function, exercise ability and quality of life for this...

2012-05-23 06:26:20

SAN FRANCISCO, May 23, 2012 /PRNewswire/ -- Advanced emphysema patients who underwent minimally invasive InterVapor(TM) (bronchoscopic thermal vapor ablation) experienced sustained improved lung function and quality of life outcomes one year after undergoing treatment, according to new data presented today at the meeting of the American Thoracic Society (ATS) in San Francisco, CA. The InterVapor procedure, pioneered by U.S.-based Uptake Medical, involves catheter-based application of precise...

2011-12-21 06:06:00

TUSTIN, Calif., Dec. 21, 2011 /PRNewswire/ -- Uptake Medical® today announced that it received Australian Therapeutic Goods Administration (TGA) approval for its InterVapor(TM) System for endoscopic lung volume reduction for the treatment of severe emphysema. InterVapor is the first non-surgical, endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body's natural healing processes without leaving implants or foreign materials...

2011-11-29 07:03:00

TUSTIN, Calif., Nov. 29, 2011 /PRNewswire/ -- Uptake Medical® today announced the first commercial use of the InterVapor(TM) System for endoscopic lung volume reduction in a patient with severe emphysema. The patient successfully underwent treatment with InterVapor, the first endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body's natural healing processes without leaving foreign materials in the lung. The patient was treated by the...

2011-09-26 02:03:00

AMSTERDAM and TUSTIN, Calif., Sept. 26, 2011 /PRNewswire/ -- Uptake Medical® today announced it has received the CE Mark (Conformite Europeenne) for the InterVapor(TM) System - the first endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body's natural healing processes without leaving foreign materials behind. The CE Mark will allow Uptake Medical to commercialize InterVapor in key markets within the European Community. This...

2011-09-06 07:03:00

TUSTIN, Calif., Sept. 6, 2011 /PRNewswire/ -- Uptake Medical® Corp., maker of InterVapor(TM), a minimally invasive treatment for severe emphysema, today announced that seasoned medical device executive Lloyd Mencinger has joined the company as European General Manager, effective September 1, 2011. Mr. Mencinger joins Uptake Medical with nearly three decades of broad functional experience with medical device leaders such as Boston Scientific, Baxter, and American Hospital...

2009-07-24 07:36:17

Lung volume reduction surgery (LVRS) can have a significantly beneficial effect in patients with severe emphysema, according to the first ever study to randomize emphysema patients to receive either LVRS or non-surgical medical care."We found lung reduction surgery is good treatment alternative for selected emphysema patients since it not only improves survival but also meaningfully improves quality of life for a period of at least five years after the operation," said lead author of the...

2008-09-25 09:00:54

Researchers at Sentara Cardiovascular Research Institute begin a new international study to explore the safety and effectiveness of stents to open airways of patients with advanced emphysema or Chronic Obstructive Pulmonary Disease (COPD). The EASE (Exhale Airway Stents for Emphysema) Trial focuses on airway bypass, an investigational technique without surgery to create new pathways to release trapped air from within diseased lung tissue, thereby helping patients with advanced widespread...

2007-09-26 09:00:11

Spiration, Inc., a developer of novel medical technology designed to benefit patients with acute and chronic conditions of the lung, today announced that the first patients have been enrolled in the company's IBV Valve Trial in the United States. The purpose of the trial is to generate safety and effectiveness data for submission to the U.S. Food and Drug Administration (FDA) for approval to market the company's IBV Valve System in the United States for the treatment of patients with...